share_log

抗新冠口服药莫诺拉韦将亮相进博会,已与国药达成框架协议

Monoravir, an oral drug against COVID-19, will be unveiled at the Expo and has reached a framework agreement with Chinese drugs.

Moomoo 24/7 ·  Oct 6, 2022 01:25
Merck & Co Inc China, a global biopharmaceutical company, has announced that it will go back to the fair from November 5 to 10, which will be the fourth year in a row that Merck & Co Inc has participated in the fair. At this Expo, Merck & Co Inc booth reaches 1000 square meters and is located in Medical Devices and Health Care Exhibition area 7.2A3-03. It will show Merck & Co Inc's cutting-edge "medicine" and vaccine product portfolio in all directions, bringing some disease prevention and treatment programs. It is worth mentioning that Merck & Co Inc's anti-novel coronavirus oral drug monoravir will also be unveiled in this Expo. According to the official website of Sinopharm Group, on September 28th, Sinopharmaceutical Group and Merck & Co Inc jointly announced that they had reached a framework agreement for cooperation on anti-novel coronavirus oral drug monoravir in China.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment